|Barbara Rogala, Alicja Kasperska-Zając|
Monoclonal anti-IgE antibody, omalizumab (Xolair, Novartis Pharma AG) as an add-on to current therapy of moderate-to-severe persistent asthma significantly alleviated the symptoms of the disease, enabled better disease control, improved quality of life, reduced rescue medication doses, exerted steroid-sparing effect. Omalizumab should be considered in patients with severe and persistent asthma who continue to show symptoms of inadequately controlled asthma despite optimal therapy.
keywords: omalizumab, astma, nieżyt nosa, omalizumab, asthma, allergic rhinitis
pages: from 83 to 86
|estimated time of download (74 kB)|